Loading
Inflammatory Bowel Diseases · Journal article
Gut Microbes · July 16, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing a systems-level conceptual framework in which epigenetic, microbiota-derived metabolite, and mitochondrial signals converge to regulate IBD pathogenesis. It synthesizes existing mechanistic and observational evidence to argue for integrated biomarker discovery and therapeutic targeting, but does not report original clinical or experimental data to test these relationships.
Narrative review. Patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Over 240 GWAS loci associated with IBD risk identified, predominantly in non-coding regions regulating immune genes, yet genetic factors alone do not account for disease onset as evidenced by modest monozygotic twin concordance. Active IBD patients exhibit dysbiosis characterized by reduced microbial diversity, depletion of Faecalibacterium prausnitzii, and expansion of pro-inflammatory taxa including adherent-invasive Escherichia coli and Fusobacterium nucleatum. Microbial metabolites, particularly short-chain fatty acids (butyrate, propionate, acetate), inhibit histone deacetylases class I and IIa and modulate DNA methylation, promoting increased histone acetylation (H3K9ac, H3K27ac) and anti-inflammatory gene expression including FOXP3 and IL-10.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review proposes an integrated conceptual framework for understanding IBD as a dynamically regulated host–microbe ecosystem, with implications for precision medicine and therapeutic development targeting epigenetic modulators and microbiota-directed interventions. However, as a mechanistic synthesis without original clinical data, it should be read as a hypothesis-generating framework requiring empirical validation through clinical trials.
This is a narrative review synthesizing mechanistic concepts and existing literature about epigenetic-microbiome-mitochondrial interactions in IBD pathogenesis, raising integrative questions rather than reporting original experimental or clinical evidence.
As stated by the source record.
Quoted from the source exactly as published.
This review proposes an integrated conceptual framework for understanding IBD as a dynamically regulated host–microbe ecosystem, with implications for precision medicine and therapeutic development targeting epigenetic modulators and microbiota-directed interventions. However, as a mechanistic synthesis without original clinical data, it should be read as a hypothesis-generating framework requiring empirical validation through clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is increasingly recognized not merely as an immune-mediated disorder, but as a systems-level condition arising from dynamic interactions among host genetics, environmental exposures, the gut microbiome, and epigenetic regulation. While genetic susceptibility confers risk, accumulating evidence indicates that epigenetic mechanisms act as molecular integrators that translate environmental and microbial signals into sustained transcriptional programs governing immune tolerance, epithelial integrity and tissue repair. Concurrently, intestinal dysbiosis, characterized by loss of short-chain fatty acid-producing commensals and expansion of pro-inflammatory taxa, reshapes host metabolism and chromatin states through microbial-derived metabolites including short-chain fatty acids, secondary bile acids, and tryptophan catabolites. These metabolites affect epigenetic enzymes and modulate the epigenetic chromatin landscape as well as mitochondrial bioenergetics, linking microbial ecology to inflammatory gene regulation. In turn, epigenetic alterations in epithelial and immune compartments influence antimicrobial defense, barrier function, and cytokine networks, thereby sculpting microbial community organization. This bidirectional microbiome-epigenome dialogue creates self-reinforcing circuits that can either sustain mucosal homeostasis or drive chronic inflammation and colitis-associated tumorigenesis. In this review, we synthesize emerging insights into the microbiome-epigenome-mitochondrial axis in IBD and propose a conceptual framework in which metabolic, microbial, and genome-mediated signals converge to determine disease trajectory. We discuss how this integrative perspective may assist biomarker discovery and therapeutic innovation, including epigenetic modulators and microbiota-targeted interventions. Understanding IBD as a dynamically regulated host-microbe ecosystem may accelerate the development of precision strategies aimed at restoring resilient mucosal equilibrium.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.